CASE REPORT article
Front. Oncol.
Sec. Thoracic Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1673836
This article is part of the Research TopicReal-World Data and Real-World Evidence in Lung Cancer Volume IIView all 6 articles
Durable Clinical Benefit from Gefitinib plus Bevacizumab in a Non-Small Cell Lung Cancer Patient with an Acquired C797S Mutation Following Osimertinib Treatment: A Case Report and Literature Review
Provisionally accepted
- Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Background: The emergence of the EGFR C797S mutation in the absence of T790M represents a common mechanism of acquired resistance to first-line Osimertinib in non-small cell lung cancer (NSCLC), posing a significant clinical challenge. Case Presentation: We present the case of a 72-year-old male diagnosed with metastatic NSCLC harboring an EGFR exon 19 deletion, who developed an acquired C797S mutation (without T790M) following 25 months of first-line Osimertinib therapy. Based on this molecular profile, the patient received a regimen of gefitinib combined with bevacizumab. This combination was well tolerated and resulted in a partial response, achieving a progression-free survival (PFS) of 15.5 months. Conclusion: This case indicates that the combination of gefitinib and bevacizumab may offer a durable clinical benefit for NSCLC patients who develop Osimertinib resistance via the C797S mutation. The observed outcomes warrant further investigation into this dual-blockade strategy, especially given the limited duration of response noted for tyrosine kinase inhibitor (TKI) monotherapy.
Keywords: non-small-cell lung cancer, epidermal growth factor receptor, C797S mutation, tyrosine kinase inhibitor, bevacizumab
Received: 26 Jul 2025; Accepted: 23 Sep 2025.
Copyright: © 2025 Tan, Dong, Li, Li, Xiong, Bao, Dai, Yue and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yuan Liu, liu_yuan2000@sina.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.